Beginning July 1, 2026, the Medicare GLP-1 Bridge Program may allow eligible Medicare Part D patients to access certain obesity-indicated GLP-1 medications, including Foundayo, Wegovy, and certain Zepbound formulations, for no more than $50 per month through December 31, 2027
However, some people may notice: decreased hunger feeling full sooner than usual mild fatigue or dizziness if calorie intake drops too quickly Monitoring nutrition and energy levels during treatment is important
If you are weighing your choices, it helps to understand the differences between oral and injectable GLP-1 options as well as microdosing and maintenance dosing strategies for staying on track long term
It contains the active drug semaglutide, which is a glucagon-like peptide-1 (GLP-1) receptor agonist that helps to decrease appetite and increase feelings of fullness, thereby aiding in weight loss
They work by mimicking the action of the naturally occurring hormone GLP-1, which is involved in regulating blood sugar and appetite
Fish and seafood (such as salmon, tuna, or shrimp): Protein-dense and satisfying without feeling heavy